Douglas B Andrews Chief Executive Officer and Director
Douglas has over 30 years of experience in the global biopharmaceutical industry, 21 of which were with the Schering-Plough Corporation, where he held a series of international roles gaining extensive experience in emerging markets such as Latin America and Eastern Europe. Douglas’s experience has included senior management roles in international business development, product management, marketing, sales and general management. His industry experience covers prescription pharmaceuticals and biochemicals, consumer healthcare products and generics.
Douglas was also the Founder & CEO of Consilient Health Ltd., where he established an innovative European “virtual” generic pharmaceutical company, combining traditional pharmaceutical industry promotional techniques with more cutting-edge commercial and operational technologies.
He  also served as a member of the Investment Committee of the National Bank of Dubai Sana, advising on  investments in the Middle East, North Africa and South Asia.

Douglas has a B.A. in History from Columbia College, U.S.A, and an M.A./M.Phil. in Balkan and Russian Area Studies from Columbia University.


Julian Attfield Chief Financial Officer, Company Secretary and Director
Julian has 17 years of experience working as a Chief Financial and Chief Executive Officer in the global biopharmaceutical industry, and has particular expertise in working with start-ups and Chinese and Indian companies.
Julian was CFO and then CEO at GeneMedix plc, (now Reliance GeneMedix plc) , an Indian AIM-listed  (Alternate Investment Market) biopharmaceutical  company, where he developed a range of biosimilar (generic biopharmaceutical) products for registration in the EU, and set up EU approved manufacturing (EU cGMP). GeneMedix floated on the Official List of the London and Singapore Stock Exchanges, acquired and divested a business in China, and set up manufacturing joint ventures in Europe and Asia. Julian led the company into an acquisition by Reliance Life Sciences, part of the large Reliance Industries Group of India, and a move onto the AIM market.
Previously, he was Director of Finance and Administration with Sigma-Genosys Ltd, a manufacturer of biomolecules, taking them from start-up to a trade sale to Sigma Aldrich.
He was recently the interim Chief Financial Officer to a portfolio of early stage companies such as Smart Holograms Ltd, a UK developer of sensor holograms for use in healthcare diagnostics.  He was UK director for the AIM flotation of BHK Inc, a Korean stem cell company.
Julian has a BA degree in Modern Languages from Exeter University and post graduate studies from Cambridge University, U.K., and qualified as a Chartered Accountant with Arthur Andersen (now part of Deloitte & Touche).


D. Bruce MurdochDirector of Planning & Business Development
Bruce has over 38 years of experience in the global biopharmaceutical industry, including general management, marketing and M&A, in the UK as well as East, South East and South Asia.  His experience includes management of global corporations and entrepreneurial enterprises.

He held senior management positions with Rhone-Poulenc, AstraZeneca, Pharmacia and Schering-Plough in the UK and Asian markets including Thailand, China, Indonesia, India and Japan. He was responsible for setting up new operations in Thailand, Korea and the Philippines.  He also managed Pharmacia’s early entry into China, with a number of joint-ventures including Sino-Swed Pharmaceutical Corporation (Astra-Kabi-Pharmacia) in Wuxi.  

He has set up several new UK enterprises to connect EU and Asian markets. He was a founder and CEO of BiOracle Ltd, a “point-of-care” diagnostic company, and remains an advisor to the Board.   He was in senior management at two biotechnology start-up companies developing new products - Senior Vice President of Gardant Pharmaceuticals (Biopharmaceutical development) and CEO of Genaderm Ltd, (anti-infective and dermatological products).

Bruce was also Chief Business Officer of Avesthagen Ltd, one of the leading biotechnology companies in India. He lead the biopharmaceutical team of 120 scientists based in India and Germany to gain approval from the India FDA for four  biosimilars (generic biopharmaceuticals)  of well-known therapeutic proteins, and Marketing Authorizations (MAs) to enter the pre-clinical phase and Good Manufacturing Practice (GMP) scale-up.

He earned an Honours Degree in Biological Sciences with Statistics from Nottingham University, U.K, and attended London Business School to study Business Finance. He has been Chairman of various country branches of IFPMA and PhRMA (pharmaceutical industry associations) including Thailand and Indonesia,


William J Hargan  Commercial Director 
Billy has over 30 years’ experience in the global biopharmaceutical industry.

He has worked for both large and small corporations in a variety of sales, marketing, business development and general management roles. He has led a number of national and international product launches and played a key role in the establishment of Hospira in Europe, Middle East and Africa following the spin-off from Abbott. 

Billy has a BSc in Physiology from the University of Glasgow  


Xiaoli Wang (William)
Country General Manager-China
William has over 17 years of experience assisting Australian, EU and American companies doing business in China.

He was Representative and Senior Business Development Manager of the Western Australian Trade Office (China), Government of Western Australia, providing market information and advice to clients on Chinese business and investment opportunities.  He monitored relevant market trends and government policy providing clients with interpretation of their commercial implications.  He also developed and maintained close relationships with key Chinese governmental agencies and industry contacts.  

Before joining the WA Trade Office, he was Manager of European and American Markets at Kainuo Co., Ltd, publicly listed on the Shanghai Stock Exchange.  He was also Division Chief of Hangzhou Import and Export Company, a state-owned international trading company, and a Division Manager of Nanjing Research Institute of Science and Technology,
a state-owned scientific research institute.

William has an Honours degree in Business Management from Taiyuan University of Technology and a Master of Philosophy from China University of Mining and Technology. He studied on the MBA course at Fudan University.


Dr Jesse Schulman
Managing Director, Stravencon Corporate Finance Ltd
Jesse Schulman is a seasoned investment banking professional with deep sector expertise in pharmaceuticals and biotechnology, and is responsible for transaction management and deal execution as head of Stravencon’s corporate finance advisory practice. He has extensive cross-border deal-making experience in M&A, fundraising and corporate partnering across the life sciences sector, and broad international contact networks in Europe and the US.  He was Director, Analysis and Research at Ferghana Partners, a US-UK life sciences corporate finance advisory firm, and a partner at life sciences transaction consultancy Capel Thompson & Homer LLP.  Previously he was VP of Healthcare Corporate Finance in the London offices of US investment bank Friedman, Billings, Ramsey, where he started out as an analyst covering European mid-cap pharmaceutical companies.  He is also the founder of Capital Systematics Ltd, an investment banking support platform, and is a former foreign correspondent.  He holds a PhD in Neurosciences from the University of California, San Diego  and a BA in Mathematics from Columbia University.


Dr Alvaro Espina
Technical Director

Alvaro Espina has over 20 years of experience in the Pharmaceutical Industry both within EU based companies and in legal consulting.

He was a Senior Partner of Yerfis, a specialised Pharmaceutical Advisory & Law Firm. He has held various senior management positions in Spyfarma (now Ferrer), responsible for the EU Emerging Markets and South American markets. He managed the process of incorporating the company into joint ventures with Spanish government.

He also led the early entry into the Spanish generic market. He has been an EU QP for various firms, where he was a member of the Board responsible for developing strategies for Internationalisation of Generic & Ethical applications. His business career includes consulting as a GMP Auditor and in Regulatory Affairs for many of the major EU markets. He also acted as a Legal consultant for EU companies advising them on pharmaceutical, regulatory and legal implications as to the market access to Spain.

Alvaro earned a Bachelor’s Degree in Pharmacy from The London School of Pharmacy. He then obtained a Master in Pharmaceutical Manufacturing and pursued a Ph. D. in Pharmacy at the University of Seville, with particular expertise in pharmaceutical sustained release formulations.  Alvaro then obtained an MBA from the Spanish Institute of Engineering and finally obtained a Bachelor’s Degree in Law, with particular expertise in business law.

 

David BiltonDirector of Procurement & Logistics
David comes with over 25 years experience in global strategic procurement, supply chain management and integrated business development in the pharmaceutical sector from both corporate and generic perspectives. He is the founder and CEO of ICE PharmaGroup a business development, procurement, sourcing and distribution operation. He has consulted in strategic and transactional procurement as well as business development for a number of pharmaceutical companies in the specialty and generic sectors. Prior to 1998 he held a series of senior positions in SmithKline Beecham within supply chain, procurement and development functions where latterly joint ventures and outsourcing were a key focus. Biochemist by discipline and member of the Chartered Institute of Purchasing and Supply. 
Recent business ventures include establishing, Generic Licensing, API Buyer, FindaPharma and Bilton By Design. Specialist consulting assignments include strategic sourcing in India, then China, product technical transfers to the Far East, strategic procurement assignments, portfolio selection for a PLC and lecturing/speaking.